Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
More than 40 types of Amyloid proteins are discovered till date
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The company does not expect this development to have any material impact on the current business operations
Subscribe To Our Newsletter & Stay Updated
